3Caldwell PHY, Murphy SB, Butow PN, et al. Clinical trials in children [J]. Lancet, 2004, 364: 803-811.
4Impicciatore P, Choonara I, Clarkson A, et al. Incidence of adverse drug reactions in paediatric in/out-patients : a systematic review an meta-analysis of prospective studies [ J]. Br J Clin Pharmacol, 2001, 52: 77-83.
5Buck ML. The FDA Modernization Act of 1997: impact on pediatric medicine [ J]. Pediatric Pharmacotherapy, 2000, 6: 12.
6Cohen SN. The pediatric pharmacology research unit (PPRU) network and its role in meeting pediatric labeling needs [ J ]. Ediatrics, 1999, 104: 644-645.
10Wang L, Zao DY, Zhang ZH. Trial of antiepilepsirine (AES) in children with epilepsy [ J ]. Brain and Development, 1999, 21: 36-40.
二级参考文献15
1Paul IM. Advances in pediatric pharmacology, therapeutics, and toxicology [J]. Adv Pediatr, 2005, 52: 321-365.
2Choonara I. Regulation of drugs for children in Europe [ J ]. BMJ, 2007, 335(7632) : 1221-1222.
3Li Wang, R Vieth, RC Landes, et al. Antiepileptie effect of antiepilepsirine in pentylentetrazol and amygdala kindled rats [J]. Epilepsy Research, 1993, 15: 1-5.
4Li Wang, Dayao Zao, Zonghao Zhang, et al. Trial of antiepilepsirine (AES) in children with epilepsy [J]. Brain & Development, 1999, 21: 36-40.
5MacLeod S, Peterson R, Wang Y, et al. Challenges in international pediatric pharmacology: a milestone meeting in Shanghai [J]. Pediatr Drugs, 2007, 9(4): 215-218.
6Shirkey HC.Drug Dosage for Infants and Children[].The Journal of The American Medical Association.1965
8Department of Health and Human Services,Food and Drug Administration.Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. Final Rule:21CFR Parts201,312,314,601.Docket No.97N-0165 .
9Carol K Taketomo,Jane H Hodding,Donna M Kraus.Pediatric Dosage Handbook[]..
10Thomas J Moore,Sheila R Weiss,Sigal Kaplan,et al.Reported Adverse Drug Events in Infants and Children Under2Years of Age[].Pediatrics.2002
